Skip to content
mapperlab
← Dashboard
Stock

AMRX

Amneal Pharmaceuticals, Inc.
Health CarePharmaceuticalsLatest close $127 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
7
27 funds tracked
Ever held
9
Current + past
New this quarter
1
Exited this quarter
0

Marquee-fund ownership over time

Aug 14, 2018Aug 9, 2024Feb 14, 2025May 15, 2026
Now
7

This quarter's activity

New positions opened

Positions exited

None.

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Renaissance Technologies$7.65$12+56%
Citadel Advisors$7.81$12+53%
Two Sigma Investments re-entered$7.81$12+53%
D.E. Shaw re-entered$7.81$12+53%
AQR Capital Management$7.81$12+53%
Millennium Management$7.81$12+53%
Point72 Asset Management re-entered$7.50$12+59%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Viking Global Investors→ $8.71-53%
Maverick Capital→ $19-16%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Amneal Pharmaceuticals, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
9
Filings · last 90d
23
Total on file
301
Recent SEC buffer
Most recent
May 12, 2026

30d / 90d windows measured from May 12, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 301 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · Amneal Pharmaceuticals, Inc.

Annual figures sourced directly from Amneal Pharmaceuticals, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$3.02B
FY2025+8% YoY
Net income
$72.06M
FY2025+162% YoY
EPS (diluted)
$0.2200
FY2025+158% YoY
Free cash flow(?)
$269.93M
FY2025+11% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Amneal Pharmaceuticals, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Point72 Asset ManagementQ2 2026open$12$12-0%
Two Sigma InvestmentsQ2 2025open$7.50$12+59%
D.E. ShawQ2 2025open$7.50$12+59%
Point72 Asset ManagementQ2 2025Q3 2025$7.50$9.39+25%
Citadel AdvisorsQ3 2024open$7.81$12+53%
Two Sigma InvestmentsQ3 2024Q1 2025$7.81$7.73-1%
D.E. ShawQ3 2024Q4 2024$7.81$9.00+15%
AQR Capital ManagementQ3 2024open$7.81$12+53%
Millennium ManagementQ3 2024open$7.81$12+53%
Renaissance TechnologiesQ3 2024open$7.65$12+56%
Viking Global InvestorsQ4 2018Q2 2019$19$8.71-53%
Maverick CapitalQ3 2018Q4 2018$22$19-16%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.